Indian Primary Market Heats Up: 10 IPOs to Raise Over ₹3,500 Crore This Week
Source: Economictimes
Arth Insight · What this means for your wallet
- A total of 10 IPOs are launching this week to raise over ₹3,500 crore.
- Symbiotec Pharmalab is the largest mainboard issue among the six scheduled launches.
- The SME segment remains active with four new offerings for retail participation.
Wealth-Impact Simulator
See what a one-time investment could grow to.
Indicative estimate for education only — not investment advice.
Explore investmentsThe Indian stock market is set for a busy week with 10 initial public offerings (IPOs) hitting the primary market to raise over ₹3,500 crore. The lineup includes six mainboard issues and four SME offerings, led by the significant Symbiotec Pharmalab IPO.
- ▸A total of 10 IPOs are launching this week to raise over ₹3,500 crore.
- ▸Symbiotec Pharmalab is the largest mainboard issue among the six scheduled launches.
- ▸The SME segment remains active with four new offerings for retail participation.
- ▸Investors should focus on company fundamentals as multiple issues compete for liquidity.
- ✓A total of 10 IPOs are launching this week to raise over ₹3,500 crore.
- ✓Symbiotec Pharmalab is the largest mainboard issue among the six scheduled launches.
- ✓The SME segment remains active with four new offerings for retail participation.
- ✓Investors should focus on company fundamentals as multiple issues compete for liquidity.
The Indian primary market is witnessing a surge in activity as 10 companies prepare to launch their initial public offerings (IPOs) this week. Collectively, these firms aim to raise more than ₹3,500 crore from investors, signaling strong confidence in the domestic equity markets. The pipeline consists of six mainboard IPOs and four issues from the Small and Medium Enterprise (SME) segment.
Symbiotec Pharmalab Leads the Mainboard Charge
Among the upcoming launches, Symbiotec Pharmalab is positioned as the largest issue of the week. The pharmaceutical firm is looking to secure substantial capital to fuel its growth and expansion plans. While Symbiotec leads the pack, five other mainboard companies are also scheduled to open their subscription windows, providing retail and institutional investors with a diverse range of sectors to choose from.
SME Sector Remains Robust
The SME segment continues to show resilience with four companies slated to go public. These smaller issues often attract significant interest from retail investors looking for high-growth opportunities, though they carry a different risk profile compared to mainboard listings. The total fundraising from these 10 entities is expected to surpass the ₹3,500 crore mark, maintaining the momentum seen in the primary market throughout the month.
What This Means for Retail Investors
For retail investors, this flurry of activity offers multiple entry points into new businesses. However, with so many issues opening simultaneously, experts suggest a cautious approach. Investors should evaluate the Grey Market Premium (GMP), company valuations, and the specific use of proceeds before committing capital. The robust pipeline suggests that the IPO party is far from over, with more companies expected to file their draft papers in the coming weeks.
- Mainboard IPOs: 6 issues scheduled to open.
- SME IPOs: 4 issues scheduled to open.
- Total Target: Over ₹3,500 crore.
- Key Player: Symbiotec Pharmalab.
This report is for informational purposes only and does not constitute financial or investment advice.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
IPO investments are subject to market risk and allotment. Read the RHP / prospectus before applying; grey-market premium (GMP) is unofficial and unreliable. Some listings may be sponsored. Not investment advice.
Frequently Asked Questions
How many IPOs are opening in India this week?
A total of 10 IPOs are opening this week, consisting of 6 mainboard issues and 4 SME issues.
Which is the biggest IPO to watch out for?
Symbiotec Pharmalab is the largest IPO scheduled for this week, aiming for a significant portion of the total ₹3,500 crore fundraising target.
What is the total amount being raised in the primary market this week?
Companies are collectively looking to raise more than ₹3,500 crore through their initial public offerings.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about IPOs
IPOBreakingSymbiotec Pharmalab Plans ₹150 Crore IPO for Debt Repayment, Expansion
Symbiotec Pharmalab, a global leader in corticosteroid and steroidal-hormone APIs, is planning an Initial Public Offering (IPO) to raise ₹150 crore. The funds are earmarked for repaying existing debt and expanding its operational capabilities. The company has shown consistent revenue and EBITDA growth, primarily driven by its international market presence, particularly in Europe.
IPOBreakingTempsens Instruments IPO GMP Hits 100% Mark; Subscription Surges 22x on Day 2
Tempsens Instruments has become the first IPO in nearly two years to see its Grey Market Premium (GMP) cross the 100% milestone. The issue has seen massive retail and institutional interest, getting subscribed 22 times by the second day of bidding.
IPOBreakingWhy IPO Investing Can Be a High-Stakes Gamble for Indian Retail Investors
While Initial Public Offerings (IPOs) often attract significant interest from Indian retail investors seeking quick gains, a global perspective suggests these investments can increasingly be a high-risk proposition. The allure of new listings must be balanced against the inherent volatility and lack of historical data, making thorough research crucial.
Related Stories
IPOBreakingSymbiotec Pharmalab Plans ₹150 Crore IPO for Debt Repayment, Expansion
Symbiotec Pharmalab, a global leader in corticosteroid and steroidal-hormone APIs, is planning an Initial Public Offering (IPO) to raise ₹150 crore. The funds are earmarked for repaying existing debt and expanding its operational capabilities. The company has shown consistent revenue and EBITDA growth, primarily driven by its international market presence, particularly in Europe.
IPOBreakingTempsens Instruments IPO GMP Hits 100% Mark; Subscription Surges 22x on Day 2
Tempsens Instruments has become the first IPO in nearly two years to see its Grey Market Premium (GMP) cross the 100% milestone. The issue has seen massive retail and institutional interest, getting subscribed 22 times by the second day of bidding.
IPOBreakingWhy IPO Investing Can Be a High-Stakes Gamble for Indian Retail Investors
While Initial Public Offerings (IPOs) often attract significant interest from Indian retail investors seeking quick gains, a global perspective suggests these investments can increasingly be a high-risk proposition. The allure of new listings must be balanced against the inherent volatility and lack of historical data, making thorough research crucial.
IPOBreakingABH Healthcare SME IPO Opens Monday: Price Band ₹96-102 Per Share
The ABH Healthcare SME IPO is set to open for subscription on Monday. The public issue is a fresh issue of 34.29 lakh equity shares, with a fixed price band of ₹96 to ₹102 per share, aiming to raise capital for the company's growth.